Journal
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
Volume 11, Issue 4, Pages 446-475Publisher
HARBORSIDE PRESS
DOI: 10.6004/jnccn.2013.0059
Keywords
-
Categories
Funding
- Bristol-Myers Squibb Company
- Genentech, Inc.
- Agensys, Inc.
- sanofi-aventis U.S. LLC
- Endo Pharmaceuticals
- GlaxoSmithKline plc
- Bayer HealthCare
- CureTech Ltd.
- Eli Lilly and Company
- Merck Co., Inc.
- Novartis Pharmaceuticals Corporation
- Onyx Pharmaceuticals, Inc.
- Alton Pharmaceuticals
- Argos Therapeutics, Inc.
- Biovex, Inc.
Ask authors/readers for more resources
Bladder cancer is the fourth most common cancer in the United States. Urothelial carcinoma that originates from the urinary bladder is the most common subtype. These NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) provide recommendations on the diagnosis and management of non muscle-invasive and muscle-invasive urothelial carcinoma of the bladder. This version of the guidelines provides extensive reorganization and updates on the principles of chemotherapy management. (JNCCN 2013;11:446-475)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
